Prostate cancer-associated mutations of SPOP impair the interactions of SPOP with androgen receptor (AR) and with bromodomain and extraterminal domain (BET) proteins, reducing their degradation and potentially increasing resistance to anti-androgen therapy and BET inhibitors22,26. This evidence concerns the gene SPOP and prostate carcinoma.